知搜-全球专利检索

  1. 登录
  2. 注册

搜索结果

179 条记录 (耗时 0.046 秒)

    HBV Polymerase Mutants
    1.
    发明申请
    HBV Polymerase Mutants 审中-公开

    公开(公告)号：US20190144840A1

    公开(公告)日：2019-05-16

    申请号：US16257784

    申请日：2019-01-25

    申请人： Transgene S.A.

    发明人： Perrine Martin ,  Nathalie Silvestre ,  Jean-Baptiste Marchand

    IPC分类号： C12N9/12 ,  C12P21/02 ,  C12N7/00 ,  C07K14/005 ,  A61K39/29 ,  C12N9/22

    摘要： The present invention relates to polymerase HBV mutant polypeptides comprising a mutated polymerase domain which is functionally disrupted for polymerase activity and fusion proteins comprising such polymerase mutant polypeptide. The present invention also relates to a nucleic acid molecule and an expression vector for expressing said polymerase mutant polypeptide as well as a composition which can be used for eliciting an immune response to HBV with the goal of providing a protective or therapeutic effect against HBV infection.

    METHOD FOR ORTHOPOXVIRUS PRODUCTION AND PURIFICATION
    4.
    发明申请
    METHOD FOR ORTHOPOXVIRUS PRODUCTION AND PURIFICATION 审中-公开
    方法生产和纯化方法

    公开(公告)号：US20140073033A1

    公开(公告)日：2014-03-13

    申请号：US14077621

    申请日：2013-11-12

    申请人： TRANSGENE S.A.

    发明人： Claude SENE ,  Sylvie CAMPOURCY ,  Yves CORDIER

    IPC分类号： C12N7/00

    CPC分类号： C12N7/025 ,  A61K35/768 ,  C12N7/00 ,  C12N7/02 ,  C12N15/86 ,  C12N2710/24152 ,  C12N2710/24251 ,  C12P21/00 ,  Y02A50/388 ,  Y02A50/39

    摘要： The present invention relates to a method for producing and purifying a wild type, an attenuated and/or a recombinant Orthopoxvirus. The present invention relates to a purified wild type, attenuated and/or recombinant Orthopoxvirus obtained by the method of the invention and to a pharmaceutical composition, preferably a vaccine, comprising said purified Orthopoxvirus for the treatment and/or the prevention a cancer, an infectious disease and/or an autoimmune disorder, and uses thereof The present invention also relates to the use of an immortalized avian cell line obtained from an avian cell belonging to the Anatidae family, in particular Cairina moschata immortalized avian cell lines comprising a nucleic acid sequence coding a telomerase reverse transcriptase (TERT) and optionally an E1A nucleic acid sequence, for the production of a wild type, attenuated and/or recombinant Orthopoxvirus according to the process of the invention

    摘要翻译： 本发明涉及野生型，减毒型和/或重组型直痘病毒的生产和纯化方法。 本发明涉及通过本发明方法获得的纯化的野生型，减毒和/或重组的直痘病毒，以及包含用于治疗和/或预防癌症的感染性的包含所述纯化的直痘病毒的药物组合物，优选疫苗 疾病和/或自身免疫性疾病及其用途本发明还涉及从属于id科家族的鸟类细胞获得的永生化鸟类细胞系的用途，特别是Cairina moschata永生化鸟类细胞系，其包含编码 根据本发明的方法生产野生型，减毒和/或重组的直链痘病毒的端粒酶逆转录酶（TERT）和任选的E1A核酸序列

    IMMORTALIZED AVIAN CELL LINES COMPRISING E1A NUCLEIC ACID SEQUENCES
    5.
    发明申请
    IMMORTALIZED AVIAN CELL LINES COMPRISING E1A NUCLEIC ACID SEQUENCES 有权
    包含E1A核酸序列的完整的AVIAN细胞系

    公开(公告)号：US20130244246A1

    公开(公告)日：2013-09-19

    申请号：US13723946

    申请日：2012-12-21

    申请人： TRANSGENE S.A.`

    发明人： Philippe Erbs ,  Marina Kapfer ,  Nathalie Silvestre

    IPC分类号： C12N15/90

    CPC分类号： C12N15/907 ,  C12N7/00 ,  C12N15/902 ,  C12N2710/24152 ,  C12N2800/80

    摘要： This invention relates to immortalized avian cells, and to the use of these cells for the production of viruses. The cells according to the invention are particularly useful for the production of recombinant viral vectors which can be used for the preparation of therapeutic and/or prophylactic compositions for the treatment of animals and more particularly humans.

    摘要翻译： 本发明涉及永生化鸟类细胞，以及这些细胞用于生产病毒的用途。 根据本发明的细胞特别可用于生产重组病毒载体，所述重组病毒载体可用于制备用于治疗动物，更特别是人的治疗和/或预防组合物。

    Immortalized avian cell lines and use thereof
    6.
    发明授权
    Immortalized avian cell lines and use thereof 失效
    永生化的禽类细胞系及其用途

    公开(公告)号：US08445270B2

    公开(公告)日：2013-05-21

    申请号：US12777731

    申请日：2010-05-11

    申请人： Jean-Marc Balloul ,  Marina Kapfer ,  Thierry Menguy

    发明人： Jean-Marc Balloul ,  Marina Kapfer ,  Thierry Menguy

    IPC分类号： C12N5/00

    CPC分类号： C12N7/025 ,  A61K35/768 ,  C12N7/00 ,  C12N7/02 ,  C12N15/86 ,  C12N2710/24152 ,  C12N2710/24251 ,  C12P21/00 ,  Y02A50/388 ,  Y02A50/39

    摘要： The present invention relates to specific immortalized avian cell lines expressing telomerase reverse transcriptase (TERT), and exhibiting distinct biologics production patterns. More particularly, the present invention relates to immortalized avian cell line capable of either amplifying Flaviviridae but not capable of amplifying Vaccinia virus strain Copenhagen (VV-COP) nor Modified Vaccinia virus Ankara (MVA), or capable of amplifying both Flaviviridae and Poxviridae. The invention further relates to the use of said immortalized avian cell lines and related methods for producing biologics, including viruses and proteins.

    摘要翻译： 本发明涉及表达端粒酶逆转录酶（TERT）的特异性永生化鸟类细胞系，并表现出不同的生物制品生产模式。 更具体地，本发明涉及能够扩增黄病毒科但不能扩增牛痘病毒株哥本哈根（VV-COP）或修饰的痘苗病毒安卡拉（MVA）或能够扩增黄病毒科和痘病毒科的永生化鸟类细胞系。 本发明还涉及使用所述永生化鸟类细胞系和相关方法来生产生物制剂，包括病毒和蛋白质。

    IMMORTALIZED AVIAN CELL LINES
    7.
    发明申请
    IMMORTALIZED AVIAN CELL LINES 审中-公开
    完全免费的AVIAN细胞线

    公开(公告)号：US20130095557A1

    公开(公告)日：2013-04-18

    申请号：US13806428

    申请日：2011-06-29

    申请人： Philippe Erbs ,  Marina Kapfer ,  Nathalie Silvestre

    发明人： Philippe Erbs ,  Marina Kapfer ,  Nathalie Silvestre

    IPC分类号： C12N5/073

    CPC分类号： C12N5/0603 ,  C12N7/00 ,  C12N15/00 ,  C12N15/907 ,  C12N2710/24052 ,  C12N2710/24152 ,  C12N2760/16152 ,  C12N2760/16252 ,  C12N2800/80

    摘要： This invention relates to immortalized avian cells, including those deposited under accession numbers 09070701, 09070702, and 09070703 at the ECACC, and to the use of these cells for the production of viruses. The cells according to the invention are particularly useful for the production of recombinant viral vectors which can be used for the preparation of therapeutic and/or prophylactic compositions for the treatment of animals and more particularly humans.

    摘要翻译： 本发明涉及永生化禽类细胞，包括在ECACC登录号为09070701,09070702和09070703的那些，以及这些细胞用于生产病毒的用途。 根据本发明的细胞特别可用于生产重组病毒载体，所述重组病毒载体可用于制备用于治疗动物，更特别是人的治疗和/或预防组合物。

    Papillomavirus vaccines
    8.
    发明授权
    Papillomavirus vaccines 有权
    乳头瘤病毒疫苗

    公开(公告)号：US08420103B2

    公开(公告)日：2013-04-16

    申请号：US12449197

    申请日：2008-01-29

    申请人： Martine Baudin ,  Jean-Marc Balloul ,  Nathalie Silvestre

    发明人： Martine Baudin ,  Jean-Marc Balloul ,  Nathalie Silvestre

    IPC分类号： A61K39/12 ,  C12N15/63 ,  A61P31/12

    CPC分类号： C07K14/005 ,  A61K2039/525 ,  C12N7/00 ,  C12N2710/20022

    摘要： A nucleic acid molecule encoding at least one papillomavirus E2 polypeptide, or a vector, an infectious viral particle or a therapeutic composition thereof is formulated into a drug product useful for treating a patient suffering from a persistent papillomavirus infection caused by at least one papillomavirus; particular such vectors are nucleic acid molecules containing a first nucleotide sequence encoding a papillomavirus E1 polypeptide and a second nucleotide sequence encoding a papillomavirus E2 polypeptide wherein the 3′ portion of the first nucleotide which in the natural content is 100% identical to the 5′ portion of the second nucleotide is modified so as to exhibit a percentage of identity between said portions of at most 75%.

    摘要翻译： 将编码至少一种乳头瘤病毒E2多肽或载体，感染性病毒颗粒或其治疗组合物的核酸分子配制成用于治疗由至少一种乳头瘤病毒引起的持续性乳头瘤病毒感染的患者的药物产品; 特定的这样的载体是含有编码乳头瘤病毒E1多肽的第一核苷酸序列和编码乳头瘤病毒E2多肽的第二核苷酸序列的核酸分子，其中第一个核苷酸的3'部分在天然含量中与5'部分100％相同 的第二核苷酸被修饰以显示所述部分之间的同一性百分比至多为75％。